Biblio
[Safety and efficacy of ruxolitinib as a salvage regimen for patients with refractory acute and chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation]. Zhonghua Xue Ye Xue Za Zhi. 2018;39(12):1026-1029.
.